Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of KOMINOX (KML001, sodium meta-arsenite) in Hormone-Refractory Prostate Cancer with Bone Metastases
2006-005607-33Phase 2Terminated
- Sponsor
- KOMINOX USA, Inc.
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sodium arsenite in prostate cancer (PCa) (2 arms), sponsored by KOMINOX USA, Inc. Primary endpoint: PSA response rate. Started Mar 2007; status: terminated.
02
Drugs
sodium arsenite
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2006-005607-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005607-33.